Dark

Check out our Dark Pool Levels

BCEL
ATRECA INC A
stock OTC

Inactive

Jun 14, 2024

0.0900USD-1.316%(-0.0012)138,651

Pre-market

0.00USD-100.000%(-0.09)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 4, 2022

04:34PM EST Atreca To Present Anti-SARS-CoV-2 Antibody Discoveries At Keystone Symposia Conference: Antibodies As Drugs Jan. 31 Benzinga

04:30PM EST Atreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone GlobeNewswire Inc

Nov 2, 2021

10:58AM EDT Atreca Q3 EPS $(0.74) Down From $(0.66) YoY Benzinga

08:30AM EDT Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2021, and provided an overview of recent developments. GlobeNewswire Inc

Oct 21, 2021

12:11PM EDT Atreca Enters Into Licensing Agreement With Bill & Melinda Gates Medical Research Institute To Develop A Monoclonal Antibody For The Prevention Of Malaria Benzinga

08:00AM EDT Atreca Enters into Licensing Agreement with Bill & Melinda Gates GlobeNewswire Inc

Oct 1, 2021

08:03AM EDT Atreca Announces Poster Presentations At Society For Immunotherapy Of Cancer Annual Meeting Nov. 12-14 Benzinga

08:00AM EDT Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two poster presentations at the SITC 2021 Annual Meeting, which is being held November 10-14, 2021 in Washington, D.C. GlobeNewswire Inc

Sep 8, 2021

04:30PM EDT Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming virtual investor conferences: GlobeNewswire Inc

Aug 11, 2021

04:53PM EDT Atreca Q2 EPS $(0.72) Down From $(0.71) YoY Benzinga

04:05PM EDT Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2021, and provided an overview of recent developments. GlobeNewswire Inc

Aug 10, 2021

02:42PM EDT The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs Benzinga

Jul 30, 2021

07:54AM EDT The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs Benzinga

Jul 29, 2021

02:30PM EDT Mid-Afternoon Market Update: Dow Jumps Over 200 Points; Tempur Sealy Shares Spike Higher Benzinga

02:06PM EDT Atreca Stock Selloff Triggered By Interim ATRC-101 Data Appears Overdone, Stifel Says Benzinga

12:10PM EDT Mid-Day Market Update: LendingClub Surges Following Strong Q2 Results; Atreca Shares Plummet Benzinga

10:26AM EDT Mid-Morning Market Update: Markets Open Higher; Mastercard Profit Beats Estimates Benzinga

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

07:03AM EDT Atreca Highlights Presentation Of Initial Clinical Data From Phase 1b Trial Of ATRC-101 In Select Advanced Solid Tumors Benzinga

07:00AM EDT Completed dose escalation portion of Phase 1b trial; ATRC-101 was well-tolerated with no dose-limiting toxicities observed GlobeNewswire Inc

Jul 26, 2021

04:39PM EDT Atreca To Host Webcast Presentation Of Initial Clinical Data From Phase 1b Trial Of ATRC-101 Jul. 29 Benzinga

04:30PM EDT Atreca to Host Webcast Presentation of Initial Clinical Data from GlobeNewswire Inc

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 19, 2021

04:30PM EDT Atreca Announces Appointment of Dr. Stacey Ma and Stephen R. Brady GlobeNewswire Inc

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jun 22, 2021

08:12AM EDT The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal Benzinga

Jun 18, 2021

07:46AM EDT The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs Benzinga

May 26, 2021

07:33AM EDT The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing Benzinga

May 25, 2021

07:53AM EDT The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal Benzinga

May 21, 2021

07:26AM EDT The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying Benzinga

May 14, 2021

08:30AM EDT Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming virtual investor conferences: GlobeNewswire Inc

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

May 13, 2021

07:33AM EDT Atreca Q1 EPS $(0.70) Up From $(0.73) YoY Benzinga

07:30AM EDT Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the first quarter ended March 31, 2021, and provided an overview of recent developments. GlobeNewswire Inc

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 6, 2021

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

Apr 14, 2021

07:51AM EDT The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead Benzinga

Apr 6, 2021

04:30PM EDT Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences: GlobeNewswire Inc

Apr 1, 2021

07:46AM EDT The Daily Biotech Pulse: Pfizer-BioNTech Preps For BLA Filing, Sonoma Surges, BioXcel Readout, Ortho Clinical Lands Contract Benzinga

Mar 10, 2021

04:38PM EST Atreca Reports Poster Presentation At American Association For Cancer Research Apr. 10 Benzinga

04:30PM EST Atreca Announces Poster Presentation at the Virtual American GlobeNewswire Inc

Feb 25, 2021

05:12PM EST Atreca Q4 EPS $(0.63) Up From $(0.72) YoY Benzinga

Feb 22, 2021

04:30PM EST Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences: GlobeNewswire Inc

Feb 8, 2021

10:12AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2021 Benzinga

05:58AM EST Jefferies Initiates Coverage On Atreca with Buy Rating, Announces Price Target of $30 Benzinga

Nov 12, 2020

08:35AM EST Atreca Q3 EPS $(0.66) Down From $(0.57) YoY Benzinga

08:30AM EST Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2020, and provided an overview of recent developments. GlobeNewswire Inc

Nov 6, 2020

08:30AM EST Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences: GlobeNewswire Inc

Oct 14, 2020

04:30PM EDT Atreca Announces Poster Presentations at the 2020 Society for GlobeNewswire Inc

Sep 3, 2020

08:00AM EDT Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences: GlobeNewswire Inc

Aug 12, 2020

10:03AM EDT HC Wainwright & Co. Maintains Buy on Atreca, Lowers Price Target to $25 Benzinga

08:32AM EDT Atreca Q2 EPS $(0.71) Up From $(3.67) YoY Benzinga

08:30AM EDT Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2020, and provided an overview of recent developments. GlobeNewswire Inc

Jul 17, 2020

05:08AM EDT 64 Biggest Movers From Yesterday Benzinga

Jul 16, 2020

02:44PM EDT Mid-Afternoon Market Update: Crude Oil Down 1%; Atreca Shares Plummet Benzinga

12:02PM EDT Mid-Day Market Update: InnerWorkings Surges Following Merger News; Tricida Shares Plunge Benzinga

10:52AM EDT Shares of Atreca, Inc. (BCEL) are currently losing nearly 18% on Thursday morning despite no stock-specific news. RTTNews

10:13AM EDT Mid-Morning Market Update: Markets Open Lower; Bank of America Earnings Top Views Benzinga

12:15AM EDT Atreca Announces Pricing of Underwritten Public Offering of Common Stock at $16/Shr RTTNews

12:06AM EDT Atreca, Inc. Announces Pricing of Underwritten Public Offering of GlobeNewswire Inc

Jul 15, 2020

04:06PM EDT Atreca Intends To Offer Shares Of Its Class A Common Stock In Public Offering RTTNews

04:03PM EDT Atreca Announces A Common Stock Offering; No Size Disclosed Benzinga

04:01PM EDT Atreca, Inc. Announces Proposed Underwritten Public Offering of GlobeNewswire Inc

Share